182 related articles for article (PubMed ID: 28591097)
1. The best treatments to use after checkpoint inhibition in melanoma.
McArthur G
Clin Adv Hematol Oncol; 2017 Apr; 15(4):242-245. PubMed ID: 28591097
[No Abstract] [Full Text] [Related]
2. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
3. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
4. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
5. The future of melanoma therapy: developing new drugs and improving the use of old ones.
Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
[No Abstract] [Full Text] [Related]
6. Diffuse recurrent cutaneous melanoma of the scalp and neck successfully treated with volumetric modulated arc therapy and concurrent ipilimumab.
Schmid RK; Harker-Murray A; Niemczyk K; Robbins JR
Pract Radiat Oncol; 2018; 8(3):174-178. PubMed ID: 29122555
[No Abstract] [Full Text] [Related]
7. Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.
Sinnamon AJ; Neuwirth MG; Gimotty PA; Gangadhar TC; Amaravadi RK; Schuchter LM; Karakousis GC
JAMA Oncol; 2018 Jan; 4(1):126-128. PubMed ID: 29145547
[TBL] [Abstract][Full Text] [Related]
8. Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
Maeda T; Yanagi T; Imafuku K; Kitamura S; Hata H; Izumi K; Ujiie H; Iwata H; Shimizu H
Int J Dermatol; 2017 Dec; 56(12):1477-1479. PubMed ID: 28762466
[No Abstract] [Full Text] [Related]
9. Novel therapies for unresectable and metastatic melanoma.
Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
[No Abstract] [Full Text] [Related]
10. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.
Mandalà M; Merelli B; Indriolo A; Tondini C
Eur J Cancer; 2018 May; 95():130-132. PubMed ID: 29559189
[No Abstract] [Full Text] [Related]
11. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
12. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
13. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
14. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
[No Abstract] [Full Text] [Related]
15. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
16. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
[No Abstract] [Full Text] [Related]
17. Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy.
Shustef E; Torres-Cabala CA; Curry JL; Tetzlaff MT; Nagarajan P; Ivan D; Prieto VG; Aung PP
Am J Dermatopathol; 2017 Aug; 39(8):e116-e118. PubMed ID: 28248716
[TBL] [Abstract][Full Text] [Related]
18. Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab.
Moreira RB; Hamieh L; Gjini E; Lako A; Krajewski KM; Yoon CH; Ott PA
J Immunother Cancer; 2017 Jul; 5(1):61. PubMed ID: 28716097
[TBL] [Abstract][Full Text] [Related]
19. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint inhibition and melanoma: Considerations in treating the older adult.
Friedman CF; Wolchok JD
J Geriatr Oncol; 2017 Jul; 8(4):237-241. PubMed ID: 28506536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
